Ar­genx scraps pro­gram in skin au­toim­mune dis­ease af­ter Vyv­gart Hytru­lo flunks an­oth­er PhI­II tri­al

Ar­genx’s au­toim­mune dis­ease drug Vyv­gart Hytru­lo flunked its sec­ond late-stage tri­al in as many months, and the com­pa­ny is aban­don­ing the in­di­ca­tion al­to­geth­er.

The Dutch biotech said Tues­day that the sub­cu­ta­neous ver­sion of its drug did not meet the pri­ma­ry end­point of the Phase III AD­DRESS study, which was in­ves­ti­gat­ing Vyv­gart Hytru­lo plus steroids in adults with pem­phi­gus vul­garis and pem­phi­gus fo­li­aceus, two com­mon types of an au­toim­mune dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER